Samsung Biologics Co Ltd (207940) — Cash Flow-to-Debt Ratio
Samsung Biologics Co Ltd (207940) has a Cash Flow-to-Debt Ratio of 0.15x as of June 2026, meaning its operating cash flow of ₩624.80 Billion could theoretically repay 0% of its total liabilities (₩4.29 Trillion) in one year. See 207940 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Samsung Biologics Co Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Samsung Biologics Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Samsung Biologics Co Ltd.
Annual Cash Flow-to-Debt Ratio for Samsung Biologics Co Ltd (2014–2025)
Year-by-year debt coverage analysis for Samsung Biologics Co Ltd. Check 207940 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.62x | ₩2.25 Trillion | ₩3.61 Trillion | ▲ +141.4% |
| 2024 | 0.26x | ₩1.66 Trillion | ₩6.43 Trillion | ▼ -3.8% |
| 2023 | 0.27x | ₩1.67 Trillion | ₩6.22 Trillion | ▲ +113.7% |
| 2022 | 0.13x | ₩953.05 Billion | ₩7.60 Trillion | ▼ -17.8% |
| 2021 | 0.15x | ₩454.60 Billion | ₩2.98 Trillion | ▲ +37.8% |
| 2020 | 0.11x | ₩202.09 Billion | ₩1.83 Trillion | ▲ +1597.8% |
| 2019 | 0.01x | ₩10.15 Billion | ₩1.56 Trillion | ▲ +136.0% |
| 2018 | -0.02x | ₩-33.02 Billion | ₩1.82 Trillion | ▼ -138.7% |
| 2017 | 0.05x | ₩149.82 Billion | ₩3.21 Trillion | ▲ +357.3% |
| 2016 | -0.02x | ₩-62.66 Billion | ₩3.45 Trillion | ▲ +78.2% |
| 2015 | -0.08x | ₩-265.51 Billion | ₩3.19 Trillion | ▲ +44.2% |
| 2014 | -0.15x | ₩-108.30 Billion | ₩724.97 Billion | — |